Further investigation revealed elevated expression of key signaling molecules and pathways, such as epidermal growth factor (EGF) and interleukin-6 (IL-6), in recurrent osteosarcomas compared to their primary counterparts (Fig. 4E). This evidence concerns the gene IL6 and osteosarcoma.